LICENSE AND ASSET PURCHASE AGREEMENTLicense and Asset Purchase Agreement • July 12th, 2022 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE AND ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of July 11, 2022 (the “Execution Date”), by and between JACOBUS PHARMACEUTICAL COMPANY, INC., a New Jersey corporation with offices located at IRL Building, 31 Schalks Crossing Road, Plainsboro, NJ (“Jacobus”) and CATALYST PHARMACEUTICALS, INC., a Delaware corporation with offices located at 355 Alhambra Circle, Suite 801, Coral Gables, FL (“Catalyst”). Jacobus and Catalyst are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SETTLEMENT AGREEMENTSettlement Agreement • July 12th, 2022 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This Settlement Agreement (including Exhibit A) (this “Agreement” or “Settlement Agreement”) is made and entered into this 11th day of July, 2022 (the “Execution Date”), by and between CATALYST PHARMACEUTICALS, INC. (“Catalyst”) and SERB SA (“SERB”), on the one hand, and JACOBUS PHARMACEUTICAL COMPANY, INC. (“Jacobus”), PANTHERX SPECIALTY LLC, and PANTHER SPECIALTY HOLDING CO. (collectively, “PantheRx”), on the other hand, (collectively, “Parties”).
